In January 2026, a Mayo Clinic-led team published the first direct comparison of postmenopausal women losing weight on tirzepatide with and without concurrent hormone therapy. The result, in The Lancet Obstetrics, Gynaecology, & Women's Health, was bigger than most clinicians expected.
Women on both tirzepatide and menopausal hormone therapy lost 19.2% of their body weight in 12+ months. Women on tirzepatide alone lost 14.0%. That is roughly 35% more weight lost on the same drug, simply by adding the therapy most of these women should arguably have been on already.
Key Takeaways
- 120 postmenopausal women tracked on tirzepatide for 12+ months
- HRT group lost 19.2% of body weight vs 14.0% without HRT (p=0.0023)
- Mean difference: 5.2 percentage points, 95% CI 1.90 to 8.54
- Study design: retrospective cohort — signal is strong but not randomized
- Likely mechanisms: lean mass preservation, better sleep, improved insulin sensitivity
- Clinical implication: if you're a candidate for HRT and already on a GLP-1, combine them
What the Study Actually Did
This was a retrospective cohort from Mayo Clinic's weight management practice. The researchers identified 120 postmenopausal women with overweight or obesity who had been on tirzepatide for at least 12 months of weight management. Half were also on some form of menopausal hormone therapy (most commonly transdermal estradiol with or without oral micronized progesterone). The other half were not.
The groups were matched on age, baseline BMI, and other clinical characteristics. Outcomes tracked included percent total body weight loss, cardiometabolic markers (HbA1c, lipids, blood pressure), and body composition where available.
The Headline Numbers
| Outcome |
HRT + Tirzepatide |
Tirzepatide Alone |
| Mean % body weight lost |
19.2% |
14.0% |
| Mean difference |
5.2 pp (95% CI 1.90 to 8.54) |
— |
| p-value |
0.0023 |
— |
| Follow-up |
12+ months |
12+ months |
A 5.2 percentage-point gap is clinically meaningful. For a 180-lb woman, that's the difference between losing 25 lb and losing 35 lb — roughly 10 lb of extra loss over the year from adding HRT.
Why This Result Isn't Surprising, If You Know the Biology
Three things happen to women's bodies at menopause that make weight loss harder:
- Lean mass drops. Estrogen supports skeletal muscle. Without it, women lose roughly 0.5% of lean mass per year through the transition. Less muscle = lower resting energy expenditure.
- Fat redistributes. Subcutaneous fat around the hips and thighs shifts to visceral fat around the abdomen. Visceral fat is metabolically worse and harder to mobilize.
- Insulin sensitivity declines. Estradiol is an insulin-sensitizing hormone. Its absence contributes to the metabolic syndrome that accelerates after menopause.
HRT directly reverses #1 and #3, and partially reverses #2. Tirzepatide is a GIP/GLP-1 dual agonist that drives caloric restriction and improves insulin sensitivity, but it also causes significant lean mass loss — roughly 10% of total weight lost on a GLP-1 is muscle, higher in older women. Adding HRT protects against that muscle loss. The combination means women lose more fat, preserve more muscle, and keep a higher resting metabolic rate, which compounds over 12 months.
For background on why menopausal weight change is not caused by HRT itself, see our analysis of the 12-year HRT body composition data. For the lean mass angle specifically, see joint pain and muscle loss in women.
The Caveats Worth Taking Seriously
This was not a randomized trial. The Lancet authors are explicit about the interpretation limits:
- Selection bias. Women who pursue HRT may also pursue other healthy behaviors — better sleep hygiene, more strength training, more consistent nutrition. Some of the 5.2-point gap may reflect that, not the hormones.
- Symptom relief confound. HRT relieves hot flashes and sleep disruption. Better sleep means lower cortisol, better appetite regulation, and more capacity for exercise. Some of the weight loss effect may be indirect through improved sleep and energy.
- No body composition in all subjects. DEXA data were available in a subset, not all 120. The lean-mass-preservation hypothesis is biologically plausible but not definitively measured in this cohort.
- Single-center, retrospective. Mayo Clinic's weight management population may not reflect a community telehealth tirzepatide patient.
A randomized trial is needed before anyone claims causality. But the biology is plausible and the effect size is large. For a clinician deciding whether to offer HRT alongside a GLP-1, waiting 5 years for an RCT is not a reasonable standard.
Who This Changes the Picture For
Three groups of women should talk to their clinician about the combination:
1. Perimenopausal or Postmenopausal Women Already on a GLP-1
If you're already taking tirzepatide or semaglutide and you have vasomotor symptoms, sleep disruption, joint pain, genitourinary symptoms, or low libido — the conventional HRT indications — adding hormone therapy now has a direct weight-loss argument on top of the usual symptom relief case. The combined program is more effective than either therapy alone for this population.
2. Women Considering Tirzepatide Who Are Also in Menopause
If you're evaluating GLP-1 therapy for weight management and you're in perimenopause or postmenopause, start the HRT conversation at the same visit. The two therapies titrate over similar timelines (8-12 weeks) and an integrated plan is easier than sequencing them.
3. Women Who Stalled on a GLP-1
The most common GLP-1 plateau in postmenopausal women is at 10-15% weight loss — exactly the ceiling the Mayo cohort hit without HRT. If you've plateaued and you have menopausal symptoms, HRT is a reasonable next move, both for symptom management and to push past the plateau.
How to Set Up the Combined Protocol
There is no single "right" combination. A common and well-tolerated regimen from menopause clinics prescribing both:
HRT component:
- Transdermal estradiol 0.05 mg patch twice weekly (lower VTE risk than oral)
- Oral micronized progesterone 100 mg at bedtime (if intact uterus)
- Optional testosterone cream 1-2 mg daily for libido/energy if deficient
Tirzepatide component:
- Standard titration: 2.5 mg weekly for 4 weeks, 5 mg for 4 weeks, then titrate by tolerance up to 10-15 mg
- Administered subcutaneously
- Continue indefinitely for weight maintenance; dose can often be reduced after target weight is reached
Labs at baseline and 3-6 months:
- Estradiol, progesterone, total and free testosterone, SHBG
- HbA1c, lipid panel, CMP, CBC
- TSH (menopausal weight gain is sometimes thyroid, not hormonal)
Most women do fine combining both. The main drug interaction to watch is cortisol rhythm changes with the combination — not a safety issue, but worth checking AM cortisol if fatigue or brain fog emerge in the first 8 weeks.
The Clinic Question
Historically, women had to piece this together across three prescribers — a gynecologist or menopause specialist for HRT, an obesity medicine doctor for tirzepatide, and a primary care doctor for labs and monitoring. That's expensive, slow, and produces inconsistent protocols.
A wave of telehealth clinics now offer integrated menopause + GLP-1 programs. One intake, one medical director, one monthly fee covering hormone therapy, compounded tirzepatide or semaglutide, labs, and provider visits. See our independent comparison at Best Online HRT Clinic for Women for pricing, coverage, and which clinics include both HRT and GLP-1 in the same program.
A few things to verify before signing up with any combined clinic:
- Is testosterone included? Most HRT-only clinics leave it out. Women lose up to half of their testosterone by menopause, and it's the hormone most associated with libido, energy, and lean mass. If the clinic doesn't prescribe it, you'll be on an incomplete regimen.
- Is the tirzepatide FDA-approved or compounded? Both are legitimate under current regulation, but compounded costs substantially less while supply constraints continue. Make sure the clinic discloses which it uses.
- What labs are included? You want baseline and follow-up hormone panels plus a metabolic panel. Labs-not-included clinics end up costing more.
- What's the provider credential? A board-certified OB-GYN, endocrinologist, or obesity medicine physician for clinical oversight, not just a nurse practitioner with no specialty training.
For the full clinic-selection framework that applies to menopause + GLP-1 programs specifically, see how to choose a TRT clinic and questions to ask any HRT clinic before the first visit.
What to Expect Month by Month
Month 1:
- Start HRT first if possible (estradiol patch + progesterone at bedtime)
- Symptom relief begins: hot flashes reduce, sleep improves within 2-3 weeks
- Begin tirzepatide 2.5 mg weekly
- Mild nausea on the GLP-1 is common the first 2 weeks
Months 2-3:
- Titrate tirzepatide to 5 mg, then 7.5 mg as tolerated
- Weight loss typically 2-4% by end of month 3
- HRT should be fully titrated; symptom control stable
Months 4-6:
- Continue titrating tirzepatide toward 10-15 mg
- Weight loss 6-10% by month 6
- Labs at month 6: confirm estradiol 50-80 pg/mL, progesterone adequate, check HbA1c, lipids
- Testosterone decision point if libido/energy still low
Months 7-12:
- Weight loss continues but at a slower rate
- Mayo cohort average: 19.2% total by 12+ months on the combination
- Strength training becomes critical to protect lean mass regardless of HRT
- Most women reach a plateau; this is the right time to reassess goals
What This Does Not Fix
HRT + tirzepatide is not a silver bullet. Three things the combination does not reliably solve:
- Severe eating disorder pathology. GLP-1s quiet food noise but do not replace treatment for binge eating disorder or bulimia. Treat the underlying condition.
- Sarcopenia from years of inactivity. Drugs preserve muscle, they do not build it. Resistance training 2-4x per week is non-negotiable, especially over age 50.
- Long-term metabolic adaptation if therapy is stopped. Stopping tirzepatide without a maintenance plan leads to most of the weight returning within 12 months. Stopping HRT restarts the menopausal trajectory. Plan for long-term use or a careful taper.
The Bottom Line
A Mayo Clinic retrospective cohort of 120 postmenopausal women, published January 2026 in The Lancet Obstetrics, Gynaecology, & Women's Health, found that menopausal hormone therapy was associated with 35% more weight loss on tirzepatide — 19.2% vs 14.0% of body weight over 12+ months. The study is not randomized, but the effect size is large and the biology is plausible.
If you're postmenopausal and taking tirzepatide, ask about HRT. If you're considering tirzepatide and you have menopausal symptoms, start both conversations at the same visit. Combined telehealth programs make the logistics much simpler than they were even two years ago.
References
- Brito JP, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology, & Women's Health. 2026;2(2):e118. DOI: 10.1016/S3050-5038(25)00145-1
- Mayo Clinic News Network. New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause. January 2026.
- Davis SR, et al. Menopause hormone therapy and cardiometabolic outcomes: 2026 position statement. Climacteric. 2026.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. PMID: 35658024.
- Rosano GMC, et al. Menopause and cardiovascular disease: the evidence. Climacteric. 2007;10 Suppl 1:19-24. PMID: 17943567.